September 30, 2020

The Niche

Knoepfler lab stem cell blog

Month: May 2016

2 min read

A sad, but not surprising day for the stem cell field as the biotech StemCells, Inc. announced that it is winding down its operations after terminating its spinal cord injury trial called the Pathway Study. The data generated so far did not justify continuing the trial. StemCells, Inc. (stock symbol STEM) has struggled financially for quite some time. In February of this year I asked if the company could cheat death given how bad things were looking and what I was hearing through the …Read More

3 min read

Here is another of my blog posts from yesterday’s CRISPR ethics, science, and policy symposium held here at UC Davis. You can read the others here, here, and here. Note as with the other posts, since I was taking notes as listening and on the fly, this post is a stream of consciousness on what the speakers said so it is rough and there are some fragments. The next panel at the UC Davis CRISPR meeting included these speakers: Michael J. Zerbe, PhD, York College …Read More

3 min read

The second session at our CRISPR meeting was really powerful. As with other posts from the UC Davis CRISPR meeting, since I was taking notes on the fly during this session, this post is a stream of bits from the different talks, often trying to capture the essence of key questions or ideas as the speakers talked so forgive the format. Overall from this session, the potential future somatic-gene therapy kind of use of CRISPR for catastrophic, fatal diseases such as Huntington’s Disease is something …Read More